Targeted Therapy in Ovarian Cancer

Table 1

Results of three pivotal trials evaluating bevacizumab in ovarian cancer. Burger et al. and Cannistra et al. evaluated bevacizumab as a single agent whereas Garcia et al. evaluated bevacizumab with low-dose metronomic oral cyclophosphamide. All studies were performed in patients with recurrent disease.

Author	Progression free survival	Overall survival	Bowel perforation
Burger et al.	3.4 months	7.29 months	0%
Cannistra et al.	4.4 months	10.7 months	11.4%
Garcia et al.	7.2 months	16.9 months	5.7%